

DAFTAR PUSTAKA

1. Karakike E, Giamarellos-Bourboulis EJ, Kyprianou M, Fleischmann-Struzek C, Pletz MW, Netea MG, et al. Coronavirus Disease 2019 as Cause of Viral Sepsis: A Systematic Review and Meta-Analysis. *Crit Care Med*. 2021;49(12):2042–57.
2. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. *JAMA - J Am Med Assoc*. 2020;324(8):782–93.
3. Koçak Tufan Z, Kayaaslan B, Mer M. COVID-19 and Sepsis. *Turkish J Med Sci*. 2021;51(S11):3301–11.
4. Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. *Crit Care Med Intensive Care Med*. 2021;41(12):1409–13.
5. Genga KR, Russell JA. Update of Sepsis in the Intensive Care Unit. *J Innate Immun*. 2017;9(5):441–55.
6. Perner A, Gordon AC, De Backer D, Dimopoulos G, Russell JA, Lipman J, et al. Sepsis: frontiers in diagnosis, resuscitation and antibiotic therapy. *Intensive Care Med*. 2016;42(12):1958–69.
7. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock. *J Am Med Assoc*. 2016;315(8):801–10.
8. Rello J, Valenzuela-Sánchez F, Ruiz-Rodríguez M, Moyano S. Sepsis: A Review of Advances in Management. *Adv Ther*. 2017;34(11):2393–411.
9. Faix JD. Biomarkers of sepsis. *Crit Rev Clin Lab Sci*. 2013;50(1):23–36.
10. Li H, Liu L, Zhang D, Xu J, Dai H, Tang N, et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. *Lancet*. 2020;395(January):19–21.
11. Song J, Park DW, Moon S, Cho HJ, Park JH, Seok H, et al. Diagnostic and prognostic value of interleukin-6, pentraxin 3, and procalcitonin levels

- among sepsis and septic shock patients: A prospective controlled study according to the Sepsis-3 definitions. *BMC Infect Dis.* 2019;19(1):1–11.
12. Tjendra Y, Al Mana AF, Espejo AP, Akgun Y, Millan NC, Gomez-Fernandez C, et al. Predicting disease severity and outcome in COVID-19 patients: A review of multiple biomarkers. *Arch Pathol Lab Med.* 2020;144(12):1465–74.
 13. Coomes EA, Haghbayan H. Interleukin-6 in Covid-19: A systematic review and meta-analysis. *Rev Med Virol.* 2020;30(6):1–9.
 14. Gorham J, Moreau A, Corazza F, Peluso L, Ponthieux F, Talamonti M, et al. Interleukine-6 in critically ill COVID-19 patients: A retrospective analysis. *PLoS One* . 2020;15(12):1–11. Available from: <http://dx.doi.org/10.1371/journal.pone.0244628>
 15. Huang L, Zhao X, Qi Y, Li H, Ye G, Liu Y, et al. Sepsis-associated severe interleukin-6 storm in critical coronavirus disease 2019. *Cell Mol Immunol.* 2020;17(10):1092–4.
 16. Karamyan VT. Between two storms, vasoactive peptides or bradykinin underlie severity of COVID-19? *Physiol Rep.* 2021;9(5):1–9.
 17. Mahmudpour M, Roozbeh J, Keshavarz M, Farrokhi S. COVID-19 cytokine storm: The anger of inflammation. *Cytokine.* 2020;133(January).
 18. Setiadi W, Rozi IE, Safari D, Daningrat WOD, Johar E, Yohan B, et al. Prevalence and epidemiological characteristics of COVID-19 after one year of pandemic in Jakarta and neighbouring areas, Indonesia: A single center study. *PLoS One* . 2022;17(5 May):1–9. Available from: <http://dx.doi.org/10.1371/journal.pone.0268241>
 19. Ge H, Wang X, Yuan X, Xiao G, Wang C, Deng T, et al. The epidemiology and clinical information about COVID-19. *Eur J Clin Microbiol Infect Dis.* 2020;39(6):1011–9.
 20. Ni Y, Alu A, Lei H, Wang Y, Wu M, Wei X. Immunological perspectives on the pathogenesis, diagnosis, prevention and treatment of COVID-19. *Mol Biomed.* 2021;2(1):1–26.
 21. Lee KY, Rhim JW, Kang JH. Immunopathogenesis of COVID-19 and early

- immunomodulators. *Clin Exp Pediatr*. 2020;63(7):239–50.
22. Krishnan A, Hamilton JP, Alqahtani SA, A.Woreta T. A narrative review of coronavirus disease 2019 (COVID-19): clinical, epidemiological characteristics, and systemic manifestations. *Intern Emerg Med* . 2021;16(4):815–30. Available from: <https://doi.org/10.1007/s11739-020-02616-5>
 23. De Bruyn A, Verellen S, Bruckers L, Geebelen L, Callebaut I, De Pauw I, et al. Secondary infection in COVID-19 critically ill patients: a retrospective single-center evaluation. *BMC Infect Dis* . 2022;22(1):1–7. Available from: <https://doi.org/10.1186/s12879-022-07192-x>
 24. Gandhi M, Yokoe DS, Havlir D V. Asymptomatic Transmission, the Achilles' Heel of Current Strategies to Control COVID-19. *COVID-19 Read*. 2020;36–9.
 25. Cordon-Cardo C, Pujadas E, Wajnberg A, Sebra R, Patel G, Firpo-Betancourt A, et al. COVID-19: Staging of a New Disease. *Cancer Cell*. 2020;38(January):19–21.
 26. Golchin A, Seyedjafari E, Ardeshirylajimi A. Mesenchymal Stem Cell Therapy for COVID-19: Present or Future. *Stem Cell Rev Reports*. 2020;16(3):427–33.
 27. Nadkarni GN, Lala A, Chang EBHL, Moreno PR, Pujadas E, Arvind V, et al. Anticoagulation , Bleeding , Mortality , and Pathology in Hospitalized Patients With COVID-19. *J Am Coll Cardiol*. 2020;76(16):1–13.
 28. Bryce C, Grimes Z, Pujadas E, Ahuja S, Beasley MB, Randy Albrecht, et al. Pathophysiology of SARS-CoV-2: targeting of endothelial cells renders a complex disease with thrombotic microangiopathy and aberrant immune response. The Mount Sinai COVID-19 autopsy experience. *Mod Pathol* . 2020;34(8):1456–1467. Available from: <https://www.medrxiv.org/content/10.1101/2020.05.18.20099960v1.abstract>
%0Ahttps://www.medrxiv.org/content/medrxiv/early/2020/05/22/2020.05.18.20099960.full.pdf
 29. Wajnberg A, Mansour M, Leven E, Bouvier NM, Patel G, Firpo-Betancourt

- A, et al. Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study. *Lancet Microbe*. 2020;1(January):283–9.
30. Hirano T. IL-6 in inflammation, autoimmunity and cancer. *Int Immunol*. 2021;33(3):127–48.
 31. Ma L, Zhang H, Yin Y ling, Guo W zhi, Ma Y qun, Wang Y bo, et al. Role of interleukin-6 to differentiate sepsis from non-infectious systemic inflammatory response syndrome. *Cytokine*. 2016;88:126–35.
 32. Kishimoto T. IL-6: From its discovery to clinical applications. *Int Immunol*. 2010;22(5):347–52.
 33. Oda S, Hirasawa H, Shiga H, Nakanishi K, Matsuda KI, Nakamura M. Sequential measurement of IL-6 blood levels in patients with systemic inflammatory response syndrome (SIRS)/sepsis. *Cytokine*. 2005;29(4):169–75.
 34. Bloos F, Reinhart K. Rapid diagnosis of sepsis. *Virulence*. 2014;5(1):154–60.
 35. Dahaba AA, Metzler H. Procalcitonin's role in the sepsis cascade. Is procalcitonin a sepsis marker or mediator? *Minerva Anesthesiol*. 2008;74(7):1–6.
 36. Tsokos M, Reichelt U, Jung R, Nierhaus A, Püschel K. Interleukin-6 and C-reactive protein serum levels in sepsis-related fatalities during the early postmortem period. *Forensic Sci Int*. 2001;119(1):47–56.
 37. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. *J Clin Invest*. 2003;112(2):299–299.
 38. Shahkar L, Keshtkar A, Mirfazeli A, Ahani A, Roshandel G. The role of IL-6 for predicting neonatal sepsis: A systematic review and meta-analysis. *Iran J Pediatr*. 2011;21(4):411–7.
 39. Zafer MM, El-Mahallawy HA, Ashour HM. Severe COVID-19 and sepsis: Immune pathogenesis and laboratory markers. *Microorganisms*. 2021;9(1):1–13.
 40. Potere N, Batticciotto A, Vecchié A, Porreca E, Cappelli A, Abbate A, et

- al. The role of IL-6 and IL-6 blockade in COVID-19. *Expert Rev Clin Immunol* . 2021;17(6):601–18. Available from: <https://doi.org/10.1080/1744666X.2021.1919086>
41. Naseem S, Iqbal R, Munir T. Role of interleukin-6 in immunity: A Review. *Int J Life Sci Res*. 2016;4(2):268–74.
42. Bhaskar S, Sinha A, Banach M, Mittoo S, Weissert R, Kass JS, et al. Cytokine Storm in COVID-19—Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper. *Front Immunol*. 2020;11(July).
43. Grivennikov SI, Greten FR, Karin M. Immunity, Inflammation, and Cancer. *Cell*. 2011;140(6):883–99.
44. Anand P, Kunnumakara AB, Sundaram C, Harikumar KB, Tharakan ST, Lai OS, et al. Cancer is a preventable disease that requires major lifestyle changes. *Pharm Res*. 2008;25(9):2097–116.
45. Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. *Nat Immunol* . 2015;16(5):448–57. Available from: <http://dx.doi.org/10.1038/ni.3153>
46. Suzuki M, Hashizume M, Yoshida H, Mihara M. Anti-inflammatory mechanism of tocilizumab, a humanized anti-IL-6R antibody: Effect on the expression of chemokine and adhesion molecule. *Rheumatol Int*. 2010;30(3):309–15.
47. Suzuki M, Hashizume M, Yoshida H, Shiina M, Mihara M. IL-6 and IL-1 synergistically enhanced the production of MMPs from synovial cells by up-regulating IL-6 production and IL-1 receptor I expression. *Cytokine* . 2010;51(2):178–83. Available from: <http://dx.doi.org/10.1016/j.cyto.2010.03.017>
48. Nakahara H, Song J, Sugimoto M, Hagihara K, Kishimoto T, Yoshizaki K, et al. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. *Arthritis Rheum*. 2003;48(6):1521–9.
49. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, et al.

- IL-6 mediates hypoferrremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. *J Clin Invest*. 2004;113(9):1271–6.
50. Yoshida Y, Tanaka T. Interleukin 6 and rheumatoid arthritis. *Biomed Res Int*. 2014;2014.
 51. Atsushi Ogata TT. Targeting of Interleukin-6 for the Treatment of Rheumatoid Arthritis: A Review and Update. *Rheumatol Curr Res*. 2014;S4(01).
 52. Ding J, Su S, You T, Xia T, Lin X, Chen Z, et al. Serum interleukin-6 level is correlated with the disease activity of systemic lupus erythematosus: a meta-analysis. *Clinics*. 2020;75:1–10.
 53. Dugar S, Choudhary C, Duggal A. Sepsis and septic shock: Guideline-based management. *Cleve Clin J Med*. 2020;87(1):53–64.
 54. Marik PE, Taeb AM. SIRS, qSOFA, and new sepsis definition. *J Thorac Dis*. 2017;9(4):943–5.
 55. Olwal CO, Nganyewo NN, Tapela K, Djomkam Zune AL, Owoicho O, Bediako Y, et al. Parallels in Sepsis and COVID-19 Conditions: Implications for Managing Severe COVID-19. *Front Immunol*. 2021;12(February):1–6.
 56. Rubin EJ, Longo DL, Baden LR. Interleukin-6 Receptor Inhibition in Covid-19 — Cooling the Inflammatory Soup. *N Engl J Med*. 2021;384(16):1564–5.
 57. Herrmann J, Adam EH, Notz Q, Helmer P, Sonntagbauer M, Ungemach-Papenberg P, et al. COVID-19 Induced Acute Respiratory Distress Syndrome—A Multicenter Observational Study. *Front Med*. 2020;7(December):1–9.
 58. Lonsdale DO, Shah R V., Lipman J. Infection, Sepsis and the Inflammatory Response: Mechanisms and Therapy. *Front Med*. 2020;7(December):10–5.
 59. Ball L, Silva PL, Giacobbe DR, Bassetti M, Zubieta-Calleja GR, Rocco PRM, et al. Understanding the pathophysiology of typical acute respiratory distress syndrome and severe COVID-19. *Expert Rev Respir Med* . 2022;16(4):437–46.

Available from:

<https://doi.org/10.1080/17476348.2022.2057300>

60. Gregoriano C, Heilmann E, Molitor A, Schuetz P. Role of procalcitonin use in the management of sepsis. *J Thorac Dis.* 2020;2(Suppl 1):S5–15.
61. Kim M hee, Choi J hyun. An Update on Sepsis Biomarkers. *Infect Chemother.* 2020;52(1):1–18.
62. Hojyo S, Uchida M, Tanaka K, Hasebe R, Tanaka Y, Murakami M, et al. How COVID-19 induces cytokine storm with high mortality. *Inflamm Regen.* 2020;40(1).
63. Grasselli G, Cattaneo E, Florio G. Secondary infections in critically ill patients with COVID-19. *Crit Care* . 2021;25(1). Available from: <https://doi.org/10.1186/s13054-021-03672-9>
64. Guan W jie, Ni Z yi, Hu Y, Liang W hua, Ou C quan, He J xing, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med.* 2020;382(18):1708–20.
65. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA - J Am Med Assoc.* 2020;323(11):1061–9.
66. Nanshan Chen, Min Zhou, Xuan Dong, Jieming Qu, Fengyun Gong, Yang Han, Yang Qiu, Jingli Wang, Ying Liu, Yuan Wei, Jia'an Xia, Ting Yu, Xinxin Zhang LZ. Characteristics of 99 Cases of 2019 Novel Coronavirus Pneumonia in Wuhan, China: A Descript study. *Lancet.* 2020;395(10223):507–13.
67. Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19 Cytokine Storm; What We Know So Far. *Front Immunol.* 2020;11(June):1–4.
68. Kim JS, Lee JY, Yang JW, Lee KH, Effenberger M, Szpirt W, et al. Immunopathogenesis and treatment of cytokine storm in COVID-19. *Theranostics.* 2020;11(1):316–29.
69. Indriyani N. Hubungan Komorbid Dengan Luaran Pasien Covid-19 Di RSUP Dr. M. Djamil Padang. *Univ Andalas* . 2021;2021 Nov 2(SP):37–

58. Available from: <http://scholar.unand.ac.id/97661/>
70. Abumayyaleh M, Nuñez-Gil IJ, El-Battrawy I, Estrada V, Becerra-Muñoz VM, Uribarri A, et al. Sepsis of Patients Infected by SARS-CoV-2: Real-World Experience From the International HOPE-COVID-19-Registry and Validation of HOPE Sepsis Score. *Front Med.* 2021;8(October):1–10.
71. Shappell CN, Klompas M, Kanjilal S, Chan C, Rhee C. Prevalence, Clinical Characteristics, and Outcomes of Sepsis Caused by Severe Acute Respiratory Syndrome Coronavirus 2 Versus Other Pathogens in Hospitalized Patients With COVID-19. *Crit Care Explor.* 2022;4(5):e0703.
72. Ginde AA, Blatchford PJ, Trzeciak S, Hollander JE, Birkhahn R, Otero R, et al. Age-related differences in biomarkers of acute inflammation during hospitalization for sepsis. *Shock.* 2014;42(2):99–107.
73. Kale S, Yende S, Kong L, Perkins A, Kellum JA, Newman AB, et al. The effects of age on inflammatory and coagulation-fibrinolysis response in patients hospitalized for pneumonia. *PLoS One.* 2010;5(11).
74. Wang HE, Shapiro NI, Griffin R, Safford MM, Judd S, Howard G. Chronic Medical Conditions and Risk of Sepsis. *PLoS One.* 2012;7(10):1–7.
75. Heubner L, Hattenhauer S, Güldner A, Petrick PL, Röbler M, Schmitt J, et al. Characteristics and outcomes of sepsis patients with and without COVID-19. *J Infect Public Health.* 2022;15(6):670–6. Available from: <https://doi.org/10.1016/j.jiph.2022.05.008>
76. Talwar D, Kumar S, Acharya S, Raisinghani N, Madaan S, Hulkoti V, et al. Interleukin 6 and Its Correlation with COVID-19 in Terms of Outcomes in an Intensive Care Unit of a Rural Hospital: A Cross-sectional Study. *Indian J Crit Care Med.* 2022;26(1):39–42.
77. Pollán BD, López GVG, Clemente PMG, González MJ, Bujalance SG, Mirá MRGG. Urinary Tract Infections in Hospitalized COVID-19 Patients, What's Up, Doc? *J Clin Med.* 2022;11(7).
78. Ohki R, Fukui Y, Morishita N, Iwata K. Increase of blood culture contamination during COVID-19 pandemic. A retrospective descriptive study. *Am J Infect Control.* 2020;49(January):1359–61.

79. Li Y, Guo J, Yang H, Li H, Shen Y, Zhang D. Comparison of culture-negative and culture-positive sepsis or septic shock: a systematic review and meta-analysis. *Crit Care* . 2021;25(1):1–9. Available from: <https://doi.org/10.1186/s13054-021-03592-8>
80. Sigakis MJG, Jewell E, Maile MD, Cinti SK, Bateman BT, Engoren M. Culture negative and culture positive sepsis: a comparison of characteristics and outcomes. *Anesth Analg*. 2019;129(5):1300–1309.
81. Kompaniyets L, Goodman AB, Belay B, Freedman DS, Sucusky MS, Lange SJ, et al. Body Mass Index and Risk for COVID-19–Related Hospitalization, Intensive Care Unit Admission, Invasive Mechanical Ventilation, and Death — United States, March–December 2020. *MMWR Surveill Summ*. 2021;70(10):355–61.
82. Daryanto B, Janardhana A, Purnomo AF. The Effect of Covid-19 Severity on Lower Urinary Tract Symptoms Manifestations. *Med Arch (Sarajevo, Bosnia Herzegovina)*. 2022;76(2):127–30.
83. Choy E, Rose-John S. Interleukin-6 as a multifunctional regulator: Inflammation, immune response, and fibrosis. *J Scleroderma Relat Disord*. 2017;2(Suppl 2):S1–5.
84. Yang D. The Biological Effects of Interleukin-6 and Their Clinical Applications in Autoimmune Diseases and Cancers. *Rheum Acta Open Access*. 2017;1(1):006–16.
85. Tanaka T, Narazaki M, Kishimoto T. IL-6 in Inflammation, Immunity, and Disease. *Cold Spring Harb Perspect Biol*. 2014;6(a016295):1–16.
86. Gautret P, Million M, Jarrot PA, Camoin-Jau L, Colson P, Fenollar F, et al. Natural history of COVID-19 and therapeutic options. *Expert Rev Clin Immunol* . 2020;16(12):1159–84. Available from: <https://doi.org/10.1080/1744666X.2021.1847640>
87. Copaescu A, Smibert O, Gibson A, Phillips EJ, Trubiano JA. The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection. *J Allergy Clin Immunol*. 2020;146(3):518-534.e1.
88. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of

patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395(10223):497–506.

89. McFadyen JD, Stevens H, Peter K. The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications. *Circ Res*. 2020;127(4):571–87.
90. Kalligeros M, Shehadeh F, Mylona EK, Benitez G, Beckwith CG, Chan PA, et al. Association of Obesity with Disease Severity Among Patients with Coronavirus Disease 2019. *Obesity*. 2020;28(7):1200–4.
91. Sari SDP, Mawanti WT, Martalena D, Listiyaningsih E, Avissa R, Latifah R, et al. Pro-inflammatory cytokine (IL-6) and total count lymphocyte profiles in COVID-19 patients with different severity levels. *J thee Med Sci(Berkala Ilmu Kedokteran)*. 2021;53(3):218–25.
92. Setyo Nugroho GM, Marhana IA, Kusumastuti EH, Semedi BP, MaimunahU, Lefi A, et al. Interleukin-6 (IL-6) expression of lung tissue in COVID-19patient severity through core biopsy post mortem. *Ann Med Surg* . 2022;82(6):104648. Available from:<https://doi.org/10.1016/j.amsu.2022.104648>
93. Mulyaningsih S. Kadar Interleukin-6 dan Feritin sebagai Prediktor Derajat Keparahan Pasien Covid-19 yang Dirawat di Rumah Sakit Umum Adam Malik. Tesis Magister (Kedokteran Klin Univ Sumatera Utara.2021;1011(1):1–8.

